ClinicalTrials.gg

Program

balstilimab

Also written as “Balstilimab”, “AGEN2034” and “Balstilimab + Zalifrelimab”.

Its studies are mostly in Uterine Cervical Neoplasms · Colorectal Neoplasms · Prostatic Neoplasms · Neoplasms · Hemangiosarcoma, led by 3 companies.

Furthest: phase 3, since Jun 4, 202110 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Agenus81 open or runningphase 3since Jun 4, 2021Mar 27, 2017Sep 2027phase 2 · NCT05608044
ImmunoGenesis11 open or runningphase 2since Jan 9, 2025Jan 9, 2025Oct 2027phase 2 · NCT06782555
Rottapharm Biotech11 open or runningphase 2since Jan 20, 2022Jan 20, 2022Dec 2026phase 2 · NCT05205330

Also a collaborator on its studies: Betta Pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 27, 2017First study: phase 2 study in Uterine Cervical NeoplasmsNew to AgenusAgenus · NCT03104699 · 211 enrolled · United States, Australia, Belgium and more
  2. Jan 19, 2018Phase 2 study in Uterine Cervical NeoplasmsAgenus · NCT03495882 · 175 enrolled · United States, Australia, Brazil and more
  3. Mar 19, 2019Phase 2 study in Uterine Cervical NeoplasmsAgenus · NCT03894215 · 211 enrolled · United States, Brazil, Mexico and more
  4. Sep 18, 2019Phase 1 study in NeoplasmsAgenus · NCT04156100 · 19 enrolled · United States
  5. Oct 16, 2020Phase 2 study in HemangiosarcomaAgenus · NCT04607200
  6. Jun 4, 2021Phase 3 study in Uterine Cervical NeoplasmsAgenus · NCT04943627 · United States, Armenia
  7. Aug 27, 2021Phase 2 study in Uterine Cervical NeoplasmsAgenus · NCT05033132 · China
  8. Jan 20, 2022Rottapharm Biotech's first study: phase 2 study in Colorectal NeoplasmsNew to Rottapharm BiotechRottapharm Biotech · NCT05205330 · 107 enrolled · Italy
  9. Nov 1, 2022Phase 2 study in Colorectal NeoplasmsAgenus · NCT05608044 · 234 enrolled · United States, Belgium, Brazil and more
  10. Jan 9, 2025ImmunoGenesis's first study: phase 2 study in Prostatic NeoplasmsNew to ImmunoGenesisImmunoGenesis · NCT06782555 · 71 enrolled · United States

Ahead

  1. Dec 2026Primary completion: phase 2 study in Colorectal NeoplasmsRottapharm Biotech · NCT05205330
  2. Sep 2027Primary completion: phase 2 study in Colorectal NeoplasmsAgenus · NCT05608044
  3. Oct 2027Primary completion: phase 2 study in Prostatic NeoplasmsImmunoGenesis · NCT06782555

TargetBeta

PDCD1 →read by rule
“A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PCD-1; PDCD1) protein, ”NCIt, by rule
“Programmed cell death protein 1 antagonist”ChEMBL 37, by rule

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
enlonstobartruleCSPC Pharmaceutical Groupphase 315
ezabenlimabBoehringer Ingelheimphase 313
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06782555Prostatic Neoplasms · United States2Active, not recruitingImmunoGenesisOct 202771
NCT05608044Colorectal Neoplasms · United States, Belgium, Brazil and more2Active, not recruitingAgenusSep 2027234
NCT05205330Colorectal Neoplasms · Italy2Active, not recruitingRottapharm BiotechDec 2026107
NCT05033132Uterine Cervical Neoplasms · China2WithdrawnAgenusDec 30, 20240
NCT04943627Uterine Cervical Neoplasms · United States, Armenia3WithdrawnAgenusOct 22, 20210
NCT04607200Hemangiosarcoma2WithdrawnAgenusSep 13, 20210
NCT04156100Neoplasms · United States1TerminatedAgenusApr 8, 202119
NCT03894215Uterine Cervical Neoplasms · United States, Brazil, Mexico and more2TerminatedAgenusMar 26, 2025211
NCT03495882Uterine Cervical Neoplasms · United States, Australia, Brazil and more2CompletedAgenusJul 15, 2022175
NCT03104699Uterine Cervical Neoplasms · United States, Australia, Belgium and more2CompletedAgenusJun 15, 2022211

How it is read

Names in the registry

  • “Balstilimab”, 4 entries
  • “AGEN2034”, 4 entries
  • “Balstilimab + Zalifrelimab”, 1 entry
  • “Balstilimab (BAL)”, 1 entry
  • “AGEN1223 and balstilimab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.